Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group. Chan A, et al. Among authors: mayer ia. Clin Breast Cancer. 2021 Feb;21(1):80-91.e7. doi: 10.1016/j.clbc.2020.09.014. Epub 2020 Oct 6. Clin Breast Cancer. 2021. PMID: 33183970 Free article. Clinical Trial.
Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA. Chakravarthy AB, et al. Among authors: mayer ia. Clin Cancer Res. 2006 Mar 1;12(5):1570-6. doi: 10.1158/1078-0432.CCR-05-2304. Clin Cancer Res. 2006. PMID: 16533783
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Guix M, et al. Among authors: mayer ia. J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180460 Clinical Trial.
Evaluation of biological agents targeted at early-stage disease.
Guix M, Mayer IA, Meszoely IM, Arteaga CL. Guix M, et al. Among authors: mayer ia. Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S25. doi: 10.1186/bcr2185. Epub 2008 Dec 18. Breast Cancer Res. 2008. PMID: 19128439 Free PMC article. No abstract available.
Does lapatinib work against HER2-negative breast cancers?
Mayer IA, Arteaga CL. Mayer IA, et al. Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179241 Free PMC article. Review.
Antiangiogenic therapies in early-stage breast cancer.
Derleth C, Mayer IA. Derleth C, et al. Among authors: mayer ia. Clin Breast Cancer. 2010;10 Suppl 1(Suppl 1):E23-31. doi: 10.3816/CBC.2010.s.004. Clin Breast Cancer. 2010. PMID: 20587404 Free PMC article. Review.
Invasive breast cancer.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R; National Comprehensive Cancer Network. Carlson RW, et al. Among authors: mayer ia. J Natl Compr Canc Netw. 2011 Feb;9(2):136-222. doi: 10.6004/jnccn.2011.0016. J Natl Compr Canc Netw. 2011. PMID: 21310842 No abstract available.
184 results